AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03871439
Drug: PF-05221304 Formulation A
RxNorm normalized name: PF-04360365
DrugBank: Ponezumab (DB15135)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg
Trial: NCT01792557
Drug: Crystallized phenol
RxNorm normalized name: Phenol
DrugBank: Phenol (DB03255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Crystallized phenol application for pilonidal disease treatment. After sacrococcygeal region of the patient is cleaned from hairs, hairs inside the sinus are removed than crystallized phenol is applied in to the cleaned sinus. Following 2 minutes of phenol exposure, crystallized phenol is removed from the sinus. Crystallized phenol application will be repeated weekly for 4 weeks.
Trial: NCT00290537
Drug: ZD6474
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZD6474 alone: Cycles 1-3 = 300 mg PO Daily x 3 Weeks; ZD6474+Carboplatin+Paclitaxel = 300 mg oral (PO) Daily or 100 mg PO Daily plus Carboplatin and Paclitaxel Every 3 Weeks.
Trial: NCT01748864
Drug: Etarfolatide (EC20)
RxNorm normalized name: Etarfolatide
DrugBank: Etarfolatide (DB11810)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00747006
Drug: TI Inhalation Powder and Humalog (Amendment 1)
RxNorm normalized name: HumaLOG
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous (sc) rapid acting analog to be administered at one half of the meal challenge visits 15 minutes before a meal. Only the last 5 - 10 patients (Type 2) will be undergoing this amendment to the protocol.
Trial: NCT00747006
Drug: TI Inhalation Powder (original protocol)
RxNorm normalized name: insulin human, rDNA origin Inhalation Powder [Exubera]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled insulin technology to be administered immediately before a meal (prandially) for glucose control in Type 1 or Type 2 diabetics
Trial: NCT01534546
Drug: Oxaliplatin capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: capecitabine：1000 mg/m2 ，bid, d1\~14 oxaliplatin：130mg/m2，iv drip for 2h，d1
Trial: NCT01534546
Drug: Oxaliplatin S-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1: 40\~60mg bid，d1\~14 （S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1 S-1 monotherapy as the same dose and schedule of the above
Trial: NCT02307396
Drug: bromperidol
RxNorm normalized name: bromperidol
DrugBank: Bromperidol (DB12401)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02307396
Drug: Flupentixole
RxNorm normalized name: flupenthixol
DrugBank: Flupentixol (DB00875)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01462175
Drug: RO5503781
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01475266
Drug: EO9 (Apaziquone)
RxNorm normalized name: Apaziquone
DrugBank: Apaziquone (DB12593)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/40 mL, Intravesical instillation, Single dose within 6 hours after TURBT
Trial: NCT01475266
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mL, Intravesical instillation, Single dose within 6 hours after TURBT
Trial: NCT03406169
Drug: Sildenafil 25 MG Oral Tablet
RxNorm normalized name: sildenafil 25 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice a day dosing
Trial: NCT02139241
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml normal saline as bolus before induction of general anesthesia
Trial: NCT02310581
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-matching buprenorphine sublingual spray delivered via single 100 μL spray
Trial: NCT00336505
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin 250 mg twice per day (BID) for 7 days, administered orally
Trial: NCT03754660
Drug: BAY1237592
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral inhalation with dry powder inhaler, single dose.
Trial: NCT00570388
Drug: Prometa Treatment Program
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 1-3•Hydroxyzine HCL 50 mg and multivitamins with minerals po one hour before flumazenil infusion. Flumazenil infusion.~Day 1•Gabapentin 300 mg po 9PM w/ hydroxyzine HCL 50 mg PRN for sleep.~Day 2•Gabapentin 600 mg po 9PM w/ hydroxyzine HCL 50 mg PRN~Day 3•Gabapentin 900 mg po 9PM w/ hydroxyzine HCL 50 mg PRN~Days 4 through 28•Gabapentin 1200 mg po 9 PM~Days 29 through 31•Gabapentin 900 mg po 9 PM~Days 32 through 34•Gabapentin 600 mg po 9 PM~Days 35 through 38•Gabapentin 300 mg po 9 PM~Flumazenil Dosing Schedule~2 mg flumazenil is given as a slow IV push. Subjects in the placebo group will receive placebo flumazenil, gabapentin, and hydroxyzine; subjects in the active group will receive flumazenil, gabapentin, and hydroxyzine per protocol.
Trial: NCT04250636
Drug: 3BNC117-LS
RxNorm normalized name: Emcor LS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 3BNC117-LS at 30mg/kg
Trial: NCT00887224
Drug: Desvenlafaxine succinate sustained release 50 mg
RxNorm normalized name: desvenlafaxine succinate 50 MG
DrugBank: Desvenlafaxine (DB06700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg tablet, once daily. 5 months open-label duration for all enrolled subjects; additional 6 months double-blind duration for randomized subjects assigned to this arm.
Trial: NCT00887224
Drug: Desvenlafaxine succinate sustained release 25 mg
RxNorm normalized name: desvenlafaxine succinate 25 MG
DrugBank: Desvenlafaxine (DB06700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg tablet for taper, once daily for 1 week
Trial: NCT00887224
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablet, once daily. 6 months double-blind duration for randomized subjects assigned to placebo.
Trial: NCT03779672
Drug: Memantine Hydrochloride 10 mg
RxNorm normalized name: memantine hydrochloride 10 MG
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Week #1: 5 mg id (am), 1 caps~* Week #2: 5 mg bid (am and pm), 2 caps~* Weeks #3-6: 5 mg am \& 2x 5 mg pm, 3 caps~* Weeks #7-8: Washout~Placebo~* Week #9: id (am), 1 caps~* Week #10: bid (am and pm), 2 caps~* Weeks #11-14: 1 caps am \& 2 caps pm, 3 caps~OR Placebo~* Week #1: id (am), 1 caps~* Week #2: bid (am and pm), 2 caps~* Weeks #3-6: 1 caps am \& 2 caps pm, 3 caps~* Weeks #7-8: Washout~Memantine~* Week #9: 5 mg id (am), 1 caps~* Week #10: 5 mg bid (am and pm), 2 caps~* Weeks #11-14: 5 mg am \& 2x 5 mg pm, 3 caps
Trial: NCT02316301
Drug: Long interval misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997. All the procedures will be diagnostic.Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain).
Trial: NCT02316301
Drug: Short interval misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997. All the procedures will be diagnostic.Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain).
Trial: NCT00505336
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral Eplerenone titrated to 50mg for duration of 12 months
Trial: NCT01697683
Drug: Probiotic Lactobacilli
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two capsules per day containing either probiotic lactobacilli or placebo for 12 weeks
Trial: NCT01697683
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01255514
Drug: high dose dexamethsone
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high dose dexamethasone : 40mg/day , D1-D4, D9-D12, IV or PO, repeat every 21days for 2cycles
Trial: NCT03516370
Drug: Saccharomyces Boulardii 250 MG
RxNorm normalized name: Saccharomyces boulardii 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: all the patient first recived scaling and root planning as a prophylactic mesaure later after that patient received intrapocket delivery of Saccharomyces Boulardii mixture.
Trial: NCT00743574
Drug: Medroxyprogesterone (Provera)
RxNorm normalized name: medroxyprogesterone Oral Tablet [Provera]
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg, PO, daily for ten days
Trial: NCT02138994
Drug: Triple Antibiotic Ointment Neosporin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to Neosporin will be required to complete 1 month of treatment comprising a screening/baseline, 2-week and 1-month visits. After 1 month the following may occur based on wound progression and/or the investigator's clinical judgment:~* Subject may continue the application of Neosporin until wound closure or~* Subject may cross over to the treatment group for 3 months
Trial: NCT01458600
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: T Diclofenac 50 mg twice daily for 12 months
Trial: NCT03378791
Drug: Iron bisglycinate Oral Tablet
RxNorm normalized name: ferrous bisglycinate / polysaccharide iron complex
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03378791
Drug: Ferrous Fumarate Oral Tablet
RxNorm normalized name: ferrous fumarate Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02413138
Drug: Somavaratan (VRS-317)
RxNorm normalized name: Prostin VR
DrugBank: Somavaratan (DB12421)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long acting recombinant human growth hormone
Trial: NCT01436175
Drug: SPD489 (Lisdexamfetamine dimesylate) + Antidepressant
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: SPD489 20mg, 30mg, 50mg, or 70mg + Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily for 52 weeks
Trial: NCT00724126
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00705406
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (buffered diluent) administered as bilateral 2-mL intramuscular injection.
Trial: NCT01079806
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets/oral solution, 0 mg, administered orally, once daily, for 48 to 96 weeks, depending on response
Trial: NCT01040312
Drug: CPT-11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPT-11 blocks certain enzymes needed for cell division and DNA repair, and it may kill cancer cells. It is a type of topoisomerase inhibitor and a type of camptothecin analog.
Trial: NCT01040312
Drug: Platinum analogues
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum compounds produce changes in DNA structure, which causes cancer cell death (apoptosis). They are typically used alone or in combination with other chemotherapy drugs.
Trial: NCT01738698
Drug: SPD489 40mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of 40 mg once-daily for up to 12 weeks
Trial: NCT01738698
Drug: SPD489 100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of 100 mg once-daily for up to 12 weeks
Trial: NCT01738698
Drug: SPD489 160mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of 160 mg once-daily for up to 12 weeks
Trial: NCT01738698
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration once-daily for 12 weeks
Trial: NCT00797056
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline SQ daily for 10 days
Trial: NCT00252382
Drug: SNS-595 Injection
RxNorm normalized name: sn-3-GPC
DrugBank: Choline alfoscerate (DB04660)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vosaroxin (formerly voreloxin or SNS-595) is a first in class anticancer quinolone derivative, non anthracycline topoisomerase II inhibitor. It induces replication dependent DNA damage by intercalating DNA and inhibiting topoisomerase II, leading to apoptosis.
Trial: NCT00154609
Drug: Gu-Sui-Bu (Davallia Divaricata)
RxNorm normalized name: Gu
DrugBank: Guanidine (DB00536)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00273052
Drug: Carvedilol Phosphate modified release formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03043443
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Natural health product for sleep problems treatment
Trial: NCT03043443
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose containing pills
Trial: NCT04056754
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects administered 4 tablets abiraterone acetate blank analog tablet twice daily in 28-day cycle.
Trial: NCT04269694
Drug: Medihoney dressing
RxNorm normalized name: MediHoney Dressing 3/4x12"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medihoney is a mixture of two honeys derived from Australia and New Zealand containing glucose oxidase and Leptospermum compounds which contribute to its antibacterial activity.
Trial: NCT02191670
Drug: METALYSE®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: weight-adjusted dosage as single bolus over 5 to 10 seconds
Trial: NCT01263132
Drug: F0434
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F0434 will be administered orally with an initial dosage of 3 capsules per day divided into 3 doses with a time interval of 8 hours between each dose. The subject will continue with this dosage for one week and afterwards, the initial dosage will be increased from 3 capsules per day divided into 3 doses with the same time interval between doses, until visit 3 (week 2).
Trial: NCT01375699
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As prescribed by treating provider.
Trial: NCT04053270
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo subcutaneous implant
Trial: NCT00300404
Drug: daraprim
RxNorm normalized name: Daraprim
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: 7614524
Drug: Extended-release 5-ISMN
RxNorm normalized name: ISMN
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extended-release 5-ISMN 60 mg once daily
Trial: 24183868
Drug: Postoperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative chemotherapy (POCT) with paclitaxel (175 mg/m²) and cisplatin (60 mg/m²) for four cycles.
Trial: 28404108
Drug: 12 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12 weeks of treatment
Trial: 10455342
Drug: G-CSF treatment
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF treatment starting at day 1
Trial: 8138680
Drug: E5 (edobacomab)
RxNorm normalized name: HYDROXYPROPYL METHYLCELLULOSE E5 [II]
DrugBank: Edobacomab (DB17779)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E5 (edobacomab) 1 mg/kg and 4 mg/kg
Trial: 15271690
Drug: Testosterone injections
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone injections + No training
Trial: 9455517
Drug: Oral azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral azithromycin prophylaxis (500 mg/week)
Trial: 14726744
Drug: Immunoglobulin (Ig)
RxNorm normalized name: FUSION PROTEIN COMPOSED OF 3 BINDING DOMAINS CONSISTING OF THREE-ALPHA-HELIX MOTIFS, EACH DERIVED FROM THE IMMUNOGLOBULIN (IG)-BINDING Z-DOMAIN OF STAPHYLOCOCCAL PROTEIN A (SPA), ENGINEERED FOR BINDING TO TWO HOMODIMER SUBUNITS OF HUMAN INTERLEUKIN 17A (
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunoglobulin (Ig) therapy
Trial: 20883991
Drug: Gonadotropin-releasing hormone
RxNorm normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gonadotropin-releasing hormone analogue (GnRH-a; gosareline acetate; Zoladex)
Trial: 31870139
Drug: Biosimilar monoclonal
RxNorm normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biosimilar monoclonal antibodies awareness
Trial: 2957052
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (MPA) 1 g daily
Trial: 8277950
Drug: High sucrose
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High sucrose diet (5600 +/- 2100 mg/kg/day)
Trial: 8277950
Drug: Low sucrose
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low sucrose diet with aspartame (38 +/- 13 mg/kg/day)
Trial: 17634183
Drug: Budesonide as
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide as needed (identical treatment to group 1 during months 1‐6, then budesonide for exacerbations as needed for months 7‐18)
Trial: 20937044
Drug: Mesalamine granules
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mesalamine granules (MG) 1.5 g once-daily
Trial: 15452681
Drug: Isradipine with
RxNorm normalized name: Isradipine
DrugBank: Isradipine (DB00270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isradipine with low dose methamphetamine (15 mg)
Trial: 1677625
Drug: PGE2 vaginal
RxNorm normalized name: dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PGE2 vaginal tablets and PGE2 vaginal pessaries
Trial: 11932561
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone (GH) treatment
Trial: 1513972
Drug: Long-term oxygen
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term oxygen therapy using portable liquid oxygen systems
Trial: 24632279
Drug: Drug-eluting stent
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-eluting stent (DES) treatment in patients with DM and type B2/C lesions
Trial: 18451188
Drug: Nefiracetam 900
RxNorm normalized name: Nefiracetam
DrugBank: Nefiracetam (DB13082)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefiracetam 900 mg
Trial: 16098636
Drug: RIX4414 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIX4414 vaccine (104.7, 105.2 or 105.8 ffu)
Trial: 19502645
Drug: Intensive medical
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive medical therapy alone
Trial: 15346657
Drug: Methimazole treatment
RxNorm normalized name: Methimazole
DrugBank: Methimazole (DB00763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methimazole treatment
Trial: 17984738
Drug: PEG 3350
RxNorm normalized name: PEG 3350
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG 3350 laxative
Trial: 23097311
Drug: SC abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: SC abatacept (125 mg/week) without methotrexate (monotherapy)
Trial: 23097311
Drug: Long-term extension
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term extension (LTE) with SC abatacept and methotrexate (combination)
Trial: 6337618
Drug: Clotrimazole 1%
RxNorm normalized name: CLOTRIMAZOLE 1% LOTION
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clotrimazole 1% cream
Trial: 29472356
Drug: 6-gene signature
RxNorm normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 6-gene signature related to B-cell receptor pathway
Trial: 8529776
Drug: Loperamide oxide
RxNorm normalized name: Loperamide oxide
DrugBank: Loperamide oxide (DB14661)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide oxide (2 mg initially, then 1 mg after each unformed stool, mean daily dose 2.7 mg)
Trial: 12935434
Drug: Amoxicilina 500
RxNorm normalized name: Amoxicilina
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicilina 500 mg capsules
Trial: 19813463
Drug: Piroxicam patch
RxNorm normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Piroxicam patch vs Piroxicam cream (intermediate visit, day 4)